QUIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUIDE (QUIDE).
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
| Metabolism | Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to its major active metabolite, norquetiapine. Minor pathways involve CYP2D6 and CYP2C9. |
| Excretion | Primarily renal (80% as unchanged drug); minor fecal (20%) |
| Half-life | 2-4 hours (prolonged in renal impairment, requiring dose adjustment) |
| Protein binding | 80-90% (primarily to albumin) |
| Volume of Distribution | 1.0-1.5 L/kg (suggests extensive tissue distribution) |
| Bioavailability | Oral: 60-75% (due to first-pass metabolism); Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: <5 minutes |
| Duration of Action | 4-6 hours (may be prolonged in hepatic or renal impairment) |
5 mg orally once daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: no adjustment. eGFR 15-29 mL/min: reduce to 2.5 mg once daily. eGFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific adjustment, but monitor for dizziness and hypotension due to age-related changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QUIDE (QUIDE).
| Breastfeeding | Excreted in breast milk; M/P ratio approximately 0.5. Limited infant exposure; however, monitor for irritability, drowsiness, and poor feeding. Caution advised; use only if clearly needed. |
| Teratogenic Risk | First trimester: Associated with increased risk of congenital heart defects, oral clefts, and neural tube defects. Second/third trimester: Risk of neonatal serotonin toxicity, persistent pulmonary hypertension, and poor neonatal adaptation syndrome. Avoid in pregnancy unless benefits outweigh risks. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis. Quetiapine is not approved for the treatment of dementia-related psychosis. Antidepressants increased the risk of suicidal thinking and behavior in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
["Hypersensitivity to quetiapine or any component of the formulation","Concomitant use with CYP3A4 inhibitors or inducers that may cause significant drug interactions (relative contraindication)"]
| Precautions | ["Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Metabolic changes: hyperglycemia, dyslipidemia, weight gain","Orthostatic hypotension and syncope","Leukopenia, neutropenia, and agranulocytosis","Cataracts (lens changes observed in animal studies)","Seizures","Body temperature dysregulation","Dysphagia","Suicide risk"] |
Loading safety data…
| Maternal: Assess for serotonin syndrome (e.g., hyperthermia, rigidity), weight gain, glucose tolerance, and blood pressure. Fetal: Ultrasound for anomalies at 18-20 weeks; neonatal observation for adaptation syndrome. |
| Fertility Effects | May cause reversible impairment of spermatogenesis in males; in females, possible disruption of menstrual cycle and reduced fertility. Discontinue use if fertility issues arise. |